About half of the patients who began dialysis due to kidney disease from ANCA-associated vasculitis (AAV) could stop it…
Articles by Margarida Maia, PhD
A greater disease burden and poorer physical quality of life were found for people with eosinophilic granulomatosis with polyangiitis (EGPA)…
In ANCA-associated vasculitis (AAV), about 1 in every 4 patients with glomerulonephritis, a type of kidney inflammation, have C3…
Use of the experimental therapy BDB-001 helps adults with ANCA-associated vasculitis (AAV) achieve at least partial disease remission, while…
Measuring circulating microRNAs — short RNA molecules that ultimately suppress gene activity — could offer doctors a less invasive way…
Treatment with the immunosuppressants cyclophosphamide, azathioprine, or rituximab after ANCA-associated vasculitis (AAV) patients have experienced a brain bleed, or…
In adults with ANCA-associated vasculitis (AAV), the amount of TWEAK protein in urine was about 50% as high when…
Vertex Pharmaceuticals has signed a license agreement with Ono Pharmaceutical to develop and market povetacicept — a B-cell-targeting…
Updated treatment guidelines from the British Society for Rheumatology favor rituximab over cyclophosphamide for active, relapsing ANCA-associated vasculitis…
Treatments for ANCA-associated vasculitis (AAV) have improved over time, but many patients still develop permanent organ damage, even though…